Department of Radiological Sciences, David Geffen School of Medicine At UCLA, Los Angeles, CA, USA.
Department of Radiology, Torrance Memorial Medical Center, Torrance, CA, USA.
Cardiovasc Intervent Radiol. 2021 Feb;44(2):325-332. doi: 10.1007/s00270-020-02691-3. Epub 2020 Nov 10.
Purpose Bronchopleural fistula is a rare but serious complication of lung ablation, as it is difficult to treat and is associated with a high mortality rate. Standard therapy often relies on surgical pleurodesis, which can be particularly problematic in patients with poor baseline lung function. A minimally invasive treatment option for bronchopleural fistula may offer an alternative to surgery for appropriate patients. This case series describes the technique, safety and efficacy of percutaneously administered synthetic hydrogel surgical sealant in the treatment of post-ablation bronchopleural fistula in five patients. Materials and methods Retrospective chart review was carried out in five consecutive patients identified to have had BPF after lung ablation between 2009 and 2017 who were treated with percutaneous administration of synthetic hydrogel surgical sealant using CT guidance. Results The procedure was successfully carried out in all patients without immediate complications, and complete resolution of air leak was achieved in four of five patients (80%). Up to the most recent follow-up, no evidence of delayed complications or recurrent air leak was present (follow-up range 1 week-8 years). Conclusion The authors' initial experience shows that targeted surgical sealant is a potentially safe and effective alternative treatment of post-ablation persistent air leak.
支气管胸膜瘘是肺消融术的一种罕见但严重的并发症,因为它难以治疗,并且与高死亡率相关。标准治疗通常依赖于外科胸膜固定术,但对于基线肺功能较差的患者来说,这可能是一个特别棘手的问题。对于合适的患者,经皮给予合成水凝胶外科密封剂可能是一种替代手术的微创治疗选择。本病例系列描述了在 2009 年至 2017 年间接受肺消融治疗后出现支气管胸膜瘘的 5 例患者中,使用 CT 引导经皮给予合成水凝胶外科密封剂的技术、安全性和疗效。
对 2009 年至 2017 年间接受肺消融治疗后出现支气管胸膜瘘的 5 例患者进行了回顾性图表分析,这些患者接受了 CT 引导下的经皮合成水凝胶外科密封剂治疗。
所有患者均成功完成了该操作,无即刻并发症,5 例患者中有 4 例(80%)完全消除了空气漏出。截至最近的随访,无迟发性并发症或复发性空气漏出的证据(随访时间 1 周至 8 年)。
作者的初步经验表明,靶向外科密封剂是治疗消融后持续性空气漏出的一种潜在安全有效的替代方法。